• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing Alumis (ALMS) Valuation After Director Srinivas Akkaraju’s $2 Million Insider Share Purchase

    Simply Wall St·12/08/2025 10:16:42
    Listen to the news

    Recent filings reveal that Alumis (ALMS) director Srinivas Akkaraju has bought about $2 million of company stock across several days. This purchase is a confidence signal that lands just as the shares gain strong momentum.

    See our latest analysis for Alumis.

    The timing of Akkaraju’s buying lines up with powerful momentum, with a 30 day share price return of 135.59 percent and a 90 day share price return of 160.42 percent pushing Alumis to $11.12. At the same time, the 1 year total shareholder return of 29.15 percent shows how quickly sentiment has shifted in the company’s favor.

    If this kind of insider conviction catches your eye, it could be worth scanning for other healthcare names showing similar strength by exploring healthcare stocks.

    With the stock up sharply yet still trading at a steep discount to Wall Street’s target, the key question now is whether Alumis remains undervalued or if the market is already pricing in its future growth.

    Price to Book of 3x: Is it justified?

    Alumis trades at roughly 3 times book value, which sits above the broader US pharmaceuticals average and implies a premium valuation at the current $11.12 share price.

    The price to book multiple compares a company’s market value to its accounting net assets. It is a common yardstick for early stage, loss making biotech names where earnings are not yet meaningful.

    For Alumis, paying more than the industry average may signal that investors are already factoring in rapid future revenue expansion and eventual commercial success, even though the company remains unprofitable and is forecast to stay that way for several years.

    That premium becomes clearer against peers. The 3 times price to book ratio sits above the 2.6 times industry benchmark but below the 4.6 times peer group average, suggesting the market assigns Alumis more potential than the sector overall but still less enthusiasm than for some closest comparables.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price to Book of 3x (OVERVALUED)

    However, setbacks in clinical trials or slower than expected adoption for ESK-001 could quickly challenge today’s optimistic expectations embedded in Alumis shares.

    Find out about the key risks to this Alumis narrative.

    Build Your Own Alumis Narrative

    If you see the story differently or want to put the numbers under your own microscope, you can build a fresh view in just minutes, starting with Do it your way.

    A great starting point for your Alumis research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.

    Looking for more investment ideas?

    If you are serious about sharpening your edge, do not stop at Alumis when you can use the Simply Wall Street Screener to uncover targeted opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.